JP6042425B2 - 肺傷害、喘息、アナフィラキシー、血管性浮腫、全身性血管透過性症候群および鼻閉を処置するためのペプチド組成物および方法 - Google Patents

肺傷害、喘息、アナフィラキシー、血管性浮腫、全身性血管透過性症候群および鼻閉を処置するためのペプチド組成物および方法 Download PDF

Info

Publication number
JP6042425B2
JP6042425B2 JP2014515930A JP2014515930A JP6042425B2 JP 6042425 B2 JP6042425 B2 JP 6042425B2 JP 2014515930 A JP2014515930 A JP 2014515930A JP 2014515930 A JP2014515930 A JP 2014515930A JP 6042425 B2 JP6042425 B2 JP 6042425B2
Authority
JP
Japan
Prior art keywords
peptide
hours
composition
induced
angioedema
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014515930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518211A5 (https=
JP2014518211A (ja
Inventor
ユリア エー． コマロバ，
ユリア エー． コマロバ，
ウズマ サキブ，
ウズマ サキブ，
スティーブン エム． ボーゲル，
スティーブン エム． ボーゲル，
アスラー ビー． マリック，
アスラー ビー． マリック，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2014518211A publication Critical patent/JP2014518211A/ja
Publication of JP2014518211A5 publication Critical patent/JP2014518211A5/ja
Application granted granted Critical
Publication of JP6042425B2 publication Critical patent/JP6042425B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2014515930A 2011-06-13 2012-06-13 肺傷害、喘息、アナフィラキシー、血管性浮腫、全身性血管透過性症候群および鼻閉を処置するためのペプチド組成物および方法 Expired - Fee Related JP6042425B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161496409P 2011-06-13 2011-06-13
US61/496,409 2011-06-13
PCT/US2012/042118 WO2012174028A2 (en) 2011-06-13 2012-06-13 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Publications (3)

Publication Number Publication Date
JP2014518211A JP2014518211A (ja) 2014-07-28
JP2014518211A5 JP2014518211A5 (https=) 2015-06-18
JP6042425B2 true JP6042425B2 (ja) 2016-12-14

Family

ID=47357694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014515930A Expired - Fee Related JP6042425B2 (ja) 2011-06-13 2012-06-13 肺傷害、喘息、アナフィラキシー、血管性浮腫、全身性血管透過性症候群および鼻閉を処置するためのペプチド組成物および方法

Country Status (15)

Country Link
US (2) US9248198B2 (https=)
EP (1) EP2717897B1 (https=)
JP (1) JP6042425B2 (https=)
KR (1) KR102042015B1 (https=)
CN (2) CN106188232B (https=)
AU (1) AU2012271781C1 (https=)
BR (1) BR112013032108B1 (https=)
CA (1) CA2838662C (https=)
DK (1) DK2717897T3 (https=)
ES (1) ES2633343T3 (https=)
IL (1) IL229771B (https=)
MX (1) MX349146B (https=)
PL (1) PL2717897T3 (https=)
WO (1) WO2012174028A2 (https=)
ZA (1) ZA201309161B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2633343T3 (es) * 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal
BR112017018665A2 (pt) * 2015-03-02 2018-04-24 The Board Of Trustees Of The University Of Illinois peptídeos para inibição de angiogênese
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用
CN110664990B (zh) * 2019-11-07 2021-03-16 江南大学 一种trpc1肽类分子在制备治疗病毒感染引起的炎症的药物中的应用
TW202204375A (zh) * 2020-04-15 2022-02-01 美商寇峇有限公司 治療冠狀病毒感染之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
EP1689355A4 (en) 2003-11-06 2008-10-01 Res Dev Foundation SELECTIVE INHIBITORS OF NUCLEAR FACTOR KB ACTIVATION AND ITS USES
CA2545422C (en) * 2003-12-03 2015-06-02 Cytopia Research Pty Ltd Tubulin inhibitors
WO2007035843A2 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US8304382B2 (en) * 2006-07-21 2012-11-06 Cristalia Productos Quimicos Farmaceuticos Ltda. Anti-inflammatory and anti-allergic cyclic peptides
WO2008011621A2 (en) * 2006-07-21 2008-01-24 The Penn State Research Foundation Protein kinase c zeta inhibition to treat vascular permeability
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
FR2940032B1 (fr) 2008-12-23 2013-08-09 Seb Sa Panier de cuisson d'aliments et systeme de cuisson correspondant
IT1392567B1 (it) * 2008-12-24 2012-03-09 Bioindustry Park Del Canavese S P A Uso di un peptide derivato da er-alfa per il ripristino della sensibilita' a composti antiestrogenici in cellule di tumore mammario
US20100190691A1 (en) * 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides
ES2633343T3 (es) * 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal

Also Published As

Publication number Publication date
US9248198B2 (en) 2016-02-02
KR20140056185A (ko) 2014-05-09
CN106188232A (zh) 2016-12-07
AU2012271781B2 (en) 2017-02-16
CN103608026A (zh) 2014-02-26
CN106188232B (zh) 2020-01-07
US20140213505A1 (en) 2014-07-31
EP2717897A2 (en) 2014-04-16
CA2838662A1 (en) 2012-12-20
MX349146B (es) 2017-07-14
AU2012271781C1 (en) 2017-09-21
ZA201309161B (en) 2015-03-25
US20140155314A1 (en) 2014-06-05
WO2012174028A3 (en) 2013-02-21
PL2717897T3 (pl) 2017-09-29
WO2012174028A2 (en) 2012-12-20
ES2633343T3 (es) 2017-09-20
JP2014518211A (ja) 2014-07-28
DK2717897T3 (en) 2017-07-17
EP2717897B1 (en) 2017-04-19
AU2012271781A1 (en) 2014-01-09
US8912139B2 (en) 2014-12-16
KR102042015B1 (ko) 2019-11-07
BR112013032108A2 (pt) 2016-11-22
CA2838662C (en) 2018-07-24
CN103608026B (zh) 2016-08-24
MX2013014650A (es) 2014-01-24
BR112013032108B1 (pt) 2021-10-26
EP2717897A4 (en) 2015-01-07
IL229771B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
JP6042425B2 (ja) 肺傷害、喘息、アナフィラキシー、血管性浮腫、全身性血管透過性症候群および鼻閉を処置するためのペプチド組成物および方法
Xie et al. Intranasal administration of recombinant Netrin-1 attenuates neuronal apoptosis by activating DCC/APPL-1/AKT signaling pathway after subarachnoid hemorrhage in rats
Yang et al. Membrane TLR9 positive neutrophil mediated MPLA protects against fatal bacterial sepsis
Johnstone et al. STIM proteins: integrators of signalling pathways in development, differentiation and disease
Zhang et al. C5aR-mediated myocardial ischemia/reperfusion injury
CN111712252A (zh) 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂
Wang et al. Glycyrrhizin attenuates caspase-11-dependent immune responses and coagulopathy by targeting high mobility group box 1
WO2008072781A1 (ja) 哺乳動物における記憶障害の抑制又は治療方法
CN106459168A (zh) 强心性类固醇拮抗剂和相关方法
Liu et al. Opticin Ameliorates Hypoxia-Induced Retinal Angiogenesis by Suppression of Integrin α2-I Domain–Collagen Complex Formation and RhoA/ROCK1 Signaling
Lv et al. Cytoglobin: a novel potential gene medicine for fibrosis and cancer therapy
US20130345143A1 (en) MODULATION OF p62 FUNCTION THROUGH THE PB1 DOMAIN
KR20130021315A (ko) Ｄｋｋ2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 그의 용도
CN119161442B (zh) 一种TrkB靶向多肽及其应用
CN102276731B (zh) 抑制可卡因诱发的高运动活性的多肽及其应用
WO2000066721A9 (en) Decreasing adipose mass by altering rsk2 activity
Atwell Targeting Sorting Nexins to Treat ErbB Dependent Breast Cancer
KR20240138585A (ko) Nampt 유래 펩타이드를 유효성분으로 포함하는 염증성 장 질환 개선, 예방 또는 치료용 조성물
WO2023137331A2 (en) Compositions and methods for treatment of cytokine storm and related conditions
WO2022173917A1 (en) Compositions and methods for treating breast cancer
Costello et al. Lysine Methylation Promotes VEGFR-2 Activation and
HK40037093B (en) Peptides and other agents for treating pain and increasing pain sensitivity
HK40037093A (en) Peptides and other agents for treating pain and increasing pain sensitivity
Schlegel Cellular receptors in cancer: CD147 and Mer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161019

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161109

R150 Certificate of patent or registration of utility model

Ref document number: 6042425

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees